TruScreen to scan 100,000 Chinese women

Martin Dillon.

A New Zealand company which resurrected an Australian biotechnology developer's cervical cancer screening technology says it has entered into a collaborative program to screen 100,000 women in China.

Parnell-based TruScreen, which offers real-time cervical cancer screening through a digital wand announced it has entered into a collaborative program with the China Doctors Association and Beijing SiweiXiangtai Tech, which is a principal distributor of the device in China.

The screening programme will be led by Professor Zhang Zhenyu from the Beijing Chaoyang Hospital and will cover every province in China - involving 100 hospitals and 1000 patients per hospital.

The programme will use TruScreen's single use sensors and the company said it expects to generate approximately $860,000 from the project over the next 12-14 months.

TruScreen's objective is to leverage off this programme and extend the reach, scope and volume of women being screened in respect of this particular programme over time.

TruScreen gained of China Food and Drug Administration regulatory approval on April 30.

TruScreen CEO Martin Dillon said he estimated the Chinese cervical cancer screening market was worth $1bn per annum.